CN106860907B - A kind of hemostatic gauze - Google Patents
A kind of hemostatic gauze Download PDFInfo
- Publication number
- CN106860907B CN106860907B CN201611264061.4A CN201611264061A CN106860907B CN 106860907 B CN106860907 B CN 106860907B CN 201611264061 A CN201611264061 A CN 201611264061A CN 106860907 B CN106860907 B CN 106860907B
- Authority
- CN
- China
- Prior art keywords
- hemostatic
- wound
- hemostatic gauze
- parts
- hemostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 51
- 230000023597 hemostasis Effects 0.000 claims abstract description 45
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 27
- 241001474374 Blennius Species 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 241001182271 Betaphycus gelatinus Species 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 11
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 11
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 11
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 13
- 235000010443 alginic acid Nutrition 0.000 claims description 13
- 229920000615 alginic acid Polymers 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000783 alginic acid Substances 0.000 claims description 11
- 229960001126 alginic acid Drugs 0.000 claims description 11
- 150000004781 alginic acids Chemical class 0.000 claims description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 10
- 239000001110 calcium chloride Substances 0.000 claims description 10
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000004804 polysaccharides Chemical class 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 239000004332 silver Substances 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 3
- 229960001395 fenbufen Drugs 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 230000035876 healing Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 description 15
- 235000019322 gelatine Nutrition 0.000 description 15
- 108010010803 Gelatin Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000008273 gelatin Substances 0.000 description 13
- 235000011852 gelatine desserts Nutrition 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 230000000025 haemostatic effect Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 108700005457 microfibrillar Proteins 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to biomedicine field more particularly to a kind of hemostatic gauzes；Including being covered on the bottom material portion for forming pollution on injury wound to avoid outer bound pair wound while effective ingredient being made to enter wound；It is covered on the hemostasis portion stopped blooding to wound in the bottom material portion；The hemostasis portion is the mixture of fibrinogen and seaweed Extraction of Eucheuma gelatinae；The hemostatic gauze that this programme provides uses a kind of novel hemostatic factor, the hemostatic factor has preferable solubization, and the hemostatic gauze that this programme provides combines physics to stop blooding on the basis of biochemistry is stopped blooding, while providing a variety of anti-inflammation and sterilization factors, it can prevent from infecting, promote healing.
Description
Technical field
The present invention relates to biomedicine field more particularly to a kind of hemostatic gauzes.
Background technique
Blood is the necessary substance of people living, however encounters fortuitous event in daily life sometimes, such as cuts the dish not small
It is anxious in one's hands or scratched by sharp weapon etc., cause human body wound and massive blood loss occur, in this case if stopping blooding meeting not in time
So that the condition of the injury of the wounded further deteriorates, or even death can be caused.Therefore first aid hemostasis and prevention infection one are to all by the world
The attention of various countries' medical field.
The main carriers form of existing hemostatic material is hemostatic gauze, stanch fibre band and tourniquet bandage.It is typical special
Sharp product has following several.
WO 01/28603 discloses a kind of injectable dosage formulations being related to for delivering composition, and the composition includes skeletonization
Albumen and hemostasis gelatin foam paste, the method for further relating to prepare the hemostasis gelatin foam paste for being suitble to injection osteogenic protein, the side
Method includes being hydrated Gelfoam powder with glutamate buffers.
Skin biopsy tissue plug involved in 5,394,886 patent of US, wherein the plug is more made of gelatin materials
It is implanted into wound by hole sponge, and expansion absorbs blood, and can be completely absorbed in patient's body.It is related to perforator
The combination of (for cutting the blade of skin) and plunger.Used plunger can be obtained by commercial channel
Gelfoam .Gelfoam is the product obtained by commercial channel, it can provide powdered gelatin, to answer as hemostat
Used in bleeding surface.The powdered gelatin is that the full glass jar or pouch to have metal cover provide, respectively by it
Open, and its content, i.e. gelatin are poured into sterile beaker or bowl.
US 5,645,849 discloses hemostatic plaster, it includes biodegradable gelatin substrate, and promoting amount of stopping blooding is coagulated
Hemase and ε aminocaproic acid.
JP 62221357 discloses the skin ointments for promoting anastalsis, it includes the thermoplastic of dissolution in a solvent
Property resin or rubber, and the jelly powder including dispersion.The product be include thermoplastic resin or rubber and collagen, gelatin or
The ointment of chitosan fine powder.
FR 2679772 is related to being used to form the granular materials of embolism, including is coated with hemostasis or coagulant
(thrombonicagent) polymer.The hemostat can be jelly powder fine crushing.
US 6,096,309 is related to hemostatic composition, it includes fibrin ferment and non-microfibrillar collagen in an aqueous medium
With the mixture of microfibrillar collagen, wherein the average fibril diameter of the microfibrillar collagen is about 3-30nm.
US 4,515,637 is related to preparing collagen-fibrin ferment hemostatic composition method, and is related to the collagen of freeze-drying
Product, it includes collagen and fibrin ferment.
US 6,045,570 is related to the jelly powder as hemostat, and is related to biological sealer, it includes gelatine size,
The gelatine size includes the gelatin powder ground.The slurry preferably includes Gelfoam powder, the powder be selected from salt water
It is mixed with the diluent of water.The slurry shows outstanding flow characteristics, i.e., it shows the smallest dilatancy
(dilatency), and easily it can inject or import by catheter lumen, especially small chamber.Therefore, which has
Outstanding characteristic of fluid.
US 6,060,461 is related to particle, especially glucan particles, its granularity is 0.5-1000 μm, and average
Aperture is 0.5-1000 nm.This document disclose by using the particle on wound in dry powder form, can promote
Formation of the blood clotting on wound.
US 3,930,052 is related to having varigrained cold water soluble gelatin composition.
US 5,225,536 is related to gelatin and amino acid granular.It has been said that such particle is suitble to mix with various resins.
The size distribution be it is such, the granularity of most of particle is 1.5-9.0 μm.
US 2003/0012741 is related to the method for preparation micronization collagen.It has been said that granularity should be no more than 20 μm, with
Just optimize the adhesive force to wound surface.
It can be seen that the main ingredient of existing hemostatic material is gelatin and chitosan, main carriers form is hemostatic yarn
Cloth, stanch fibre band, tourniquet bandage.But chitosan and gelatin are all not soluble in water, and it is mainly reached only by calcium ion
The effect of blood, but calcium ion is easy occluding vascular in blood, causes thrombus, this can bring certain side effect.
So needing a kind of novel hemostatic gauze, mainly passes through water-soluble hemostatic factor and realize hemostasis.
Summary of the invention
The purpose of the present invention is to provide a kind of hemostatic gauzes, it is intended to which the hemostasis composition for solving present hemostatic gauze is insoluble
In the water the problem of.
The present invention is implemented as follows: a kind of hemostatic gauze, including be covered on injury wound to avoid outer bound pair wound
Mouth forms the bottom material portion for polluting while effective ingredient being made to enter wound；It is covered on stopping blooding in the bottom material portion to wound
Hemostasis portion；The hemostasis portion is the mixture of fibrinogen and seaweed Extraction of Eucheuma gelatinae.It is mentioned by using seaweed Eucheuma
Take object as new hemostasis composition, which is a kind of hemostatic factor of solubility, can be stopped to avoid existing
Blood factor problem not soluble in water.
A further technical solution of the present invention is: the hemostasis portion includes 1-5 parts of fibrinogen and 95-99 parts of sea
Algae Extraction of Eucheuma gelatinae.Increase the fibrinogen of fraction to play the role of auxiliary hemostasis.
A further technical solution of the present invention is: the seaweed Extraction of Eucheuma gelatinae includes 1-54 parts of algal polysaccharides；Seaweed
1-20 parts of protein acid complex salt；1-10 parts of algin colloid；1-15 parts of alginic acid rouge；1-96 parts of glue protein.
A further technical solution of the present invention is: further including the gel section mixed with the hemostasis portion.The hemostasis portion
Itself it is a kind of liquid, in order to further increase the concentration in the hemostasis portion accommodated in bottom material portion, addition gel section can be passed through
Mode makes the gelation of hemostasis portion.
A further technical solution of the present invention is: the gel section is calcium chloride.Made by the calcium chloride of excessive addition
The gelation of hemostasis portion, while calcium chloride itself also has certain anastalsis.
A further technical solution of the present invention is: further including anti-inflammatory factors.Make the hemostasis by adding anti-inflammatory factors
Gauze further realizes the effect of anti-inflammatory on the basis for realizing haemostatic effect.
A further technical solution of the present invention is: the anti-inflammatory factors are selected from nano silver, aspirin, acetparaminosalol
One or more of sweet smell, Diclofenac, Indomethacin, brufen, fenbufen.
A further technical solution of the present invention is: the nanometer silver concentration is 5-500 ppm.When use nano silver as
It sets nanometer silver concentration to when anti-inflammatory factors to play preferable effect for 5-500 ppm.
A further technical solution of the present invention is: the bottom material portion is nonwoven gauze.Hemostasis portion is needed in default of intensity
It depends on certain bottom material, nonwoven gauze is relatively suitable as bottom material, and use scope is wide, low in cost, production technology
Simply.
A further technical solution of the present invention is: the bottom material portion is degradable biological bandage.Hemostasis portion is in default of strong
Degree needs to depend on certain bottom material, and degradable biological bandage is relatively suitable as bottom material, and use scope is wide, at low cost
Honest and clean, simple production process.
The beneficial effects of the present invention are: the hemostatic gauze that this programme provides uses a kind of novel hemostatic factor, the hemostasis
The factor has preferable solubization, and the hemostatic gauze that this programme provides combines physics to stop blooding on the basis of biochemistry is stopped blooding,
A variety of anti-inflammation and sterilization factors are provided simultaneously, can prevent from infecting, promote healing.
Specific embodiment
Present solution provides a kind of hemostatic gauzes, including are covered on injury wound and form dirt to avoid outer bound pair wound
The bottom material portion for contaminating while effective ingredient being made to enter wound；It is covered on the hemostasis portion stopped blooding to wound in the bottom material portion；
The hemostasis portion is the mixture of fibrinogen and seaweed Extraction of Eucheuma gelatinae.By using seaweed Extraction of Eucheuma gelatinae conduct
New hemostasis composition, the seaweed Extraction of Eucheuma gelatinae are a kind of hemostatic factors of solubility, can be to avoid existing hemostatic factor not
The problem of being dissolved in water.
The hemostasis portion includes 1-5 parts of fibrinogen and 95-99 parts of seaweed Extraction of Eucheuma gelatinae.Increase fraction
Fibrinogen with play the role of auxiliary hemostasis.
The seaweed Extraction of Eucheuma gelatinae includes 1-54 parts of algal polysaccharides；1-20 parts of extra large alginic acid complex salt；Algin colloid
1-10 parts；1-15 parts of alginic acid rouge；1-96 parts of glue protein.
Preferably, the hemostatic gauze further includes the gel section mixed with the hemostasis portion.The hemostasis portion itself is
A kind of liquid can be made to further increase the concentration in the hemostasis portion accommodated in bottom material portion by way of adding gel section
Obtain the gelation of hemostasis portion.
The gel section is calcium chloride.Make the gelation of hemostasis portion, while calcium chloride sheet by the calcium chloride of excessive addition
Body also has certain anastalsis.
The hemostatic gauze further includes anti-inflammatory factors.The hemostatic gauze is made to realize hemostasis by adding anti-inflammatory factors
The effect of anti-inflammatory is further realized on the basis of effect.
The anti-inflammatory factors are selected from nano silver, aspirin, acetparaminosalol sweet smell, Diclofenac, Indomethacin, Bu Luo
One or more of fragrant, fenbufen.
The nanometer silver concentration is 5-500 ppm.Nanometer silver concentration is arranged when using nano silver as anti-inflammatory factors
For preferable effect can be played for 5-500 ppm.
The bottom material portion is nonwoven gauze.Hemostasis portion needs to depend on certain bottom material in default of intensity, nonwoven
Gauze is relatively suitable as bottom material, and use scope is wide, low in cost, simple production process.
The bottom material portion is degradable biological bandage.Hemostasis portion in default of intensity need to depend on certain bottom material it
On, degradable biological bandage is relatively suitable as bottom material, and use scope is wide, low in cost, simple production process.
Illustrate the validity for the hemostatic gauze that this programme provides followed by experimental data.
Experiment one: design two groups of samples of A, B, Sample A first be hemostatic gauze, below four be common gauze, sample
B first be common gauze, below four be common gauze.It wherein include hemostasis portion and gel on hemostatic gauze in A group sample
Portion, wherein hemostasis portion include 1%(mass fraction, similarly hereinafter) fibrinogen and 99% seaweed Extraction of Eucheuma gelatinae, seaweed Qi
It include 54% algal polysaccharides, 20% extra large alginic acid complex salt, 10% seaweed protein colloid, 15% alginic acid in unicorn acid extract
Rouge, 1% glue protein.Gel section is calcium chloride.Nano silver also containing 500 ppm.
Experiment performs the following operation: being dripped off in ten seconds with buret with 0.5 milliliter of pig blood, opens yarn after 50 seconds
Cloth inspection.
As a result, A group has shallow bloodstain in second gauze, but stops permeating to third piece, B group is all thoroughly to the 5th.It can be seen that A
Group haemostatic effect is well compared with B group.
Control experiment: with experiment one two groups of samples of identical A, B, wherein A group first be hemostatic gauze, below four
For common gauze, B group first is common gauze, below four be common gauze, check experiment adds colour developing to refer to 0.5 milliliter of water
Show that agent is dripped off in ten seconds with buret, gauze inspection is opened after 50 seconds, as a result, two groups of A, B is thoroughly to the 5th.
Experiment two: zoopery.
Experimental method: choosing microspecies black pig one, is pierced into 15 in experiment pig limb artery position with 5 millimeters of diameter of cones
Mm depth checks whether there is blood ejection after extraction, push down wound with ten identical test pieces and check that bloodstain permeates feelings after five minutes
Condition.
This experiment is first in left hind, according to above method, makes and pushes down wound with hemostatic gauze ten after wound, and 5 minutes
Inspection result afterwards.As a result, it has been found that stopping blooding in third piece hemostatic gauze.Wherein including hemostasis portion and gel section on hemostatic gauze, wherein
Hemostasis portion include 5%(mass fraction, similarly hereinafter) fibrinogen and 95% seaweed Extraction of Eucheuma gelatinae, seaweed kylin acid extract
It include 25% algal polysaccharides in object, 10% extra large alginic acid complex salt, 5% seaweed protein colloid, 10% alginic acid rouge, 50%
Glue protein.Gel section is calcium chloride.Nano silver also containing 250 ppm.
Then do wound in right hind with same method, then with common gauze ten push down wound, after five minutes the tenth according to
Right oozing of blood, without haemostatic effect.It is identical to repeat experimental result.
Experiment three: zoopery.
Experimental method: choosing microspecies black pig one, is pierced into 15 in experiment pig limb artery position with 5 millimeters of diameter of cones
Mm depth checks whether there is blood ejection after extraction, push down wound with ten identical test pieces and check that bloodstain permeates feelings after five minutes
Condition.
This experiment is first in left hind, according to above method, makes and pushes down wound with hemostatic gauze ten after wound, and 5 minutes
Inspection result afterwards.As a result, it has been found that stopping blooding in the 9th hemostatic gauze.Wherein including hemostasis portion and gel section on hemostatic gauze, wherein
Hemostasis portion include 3%(mass fraction, similarly hereinafter) fibrinogen and 97% seaweed Extraction of Eucheuma gelatinae, seaweed kylin acid extract
It include 1% algal polysaccharides, 1% extra large alginic acid complex salt, 1% seaweed protein colloid, 1% alginic acid rouge, 96% glue in object
Protein.Gel section is calcium chloride.Nano silver also containing 100 ppm.
Then do wound in right hind with same method, then with common gauze ten push down wound, after five minutes the tenth according to
Right oozing of blood, without haemostatic effect.It is identical to repeat experimental result.
The hemostatic gauze that this programme provides uses a kind of novel hemostatic factor, which has preferable molten water
Property, the hemostatic gauze that this programme provides combines physics to stop blooding on the basis of biochemistry is stopped blooding, while providing a variety of anti-inflammatory and killing
Bacteria factor can prevent from infecting, and promote healing.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (8)
1. a kind of hemostatic gauze, it is characterised in that: polluted including being covered on injury wound to be formed to avoid outer bound pair wound
Effective ingredient is set to enter the bottom material portion of wound simultaneously；It is covered on the hemostasis portion stopped blooding to wound in the bottom material portion；Institute
The mixture that hemostasis portion is fibrinogen and seaweed Extraction of Eucheuma gelatinae is stated, the hemostasis portion includes 1-5 parts of fibrin
The former seaweed Extraction of Eucheuma gelatinae with 95-99 parts, the seaweed Extraction of Eucheuma gelatinae includes 1-54 parts of algal polysaccharides；Extra large alginic acid
1-20 parts of complex salt；1-10 parts of seaweed protein colloid；1-15 parts of alginic acid rouge；1-96 parts of glue protein.
2. hemostatic gauze according to claim 1, it is characterised in that: further include the gel mixed with the hemostasis portion
Portion.
3. hemostatic gauze according to claim 2, it is characterised in that: the gel section is calcium chloride.
4. hemostatic gauze according to claim 1, it is characterised in that: further include anti-inflammatory factors.
5. hemostatic gauze according to claim 4, it is characterised in that: the anti-inflammatory factors be selected from nano silver, aspirin,
One or more of acetparaminosalol sweet smell, Diclofenac, Indomethacin, brufen, fenbufen.
6. hemostatic gauze according to claim 5, it is characterised in that: the nanometer silver concentration is 5-500ppm.
7. hemostatic gauze according to claim 1, it is characterised in that: the bottom material portion is nonwoven gauze.
8. hemostatic gauze according to claim 1, it is characterised in that: the bottom material portion is degradable biological bandage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611264061.4A CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611264061.4A CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106860907A CN106860907A (en) | 2017-06-20 |
| CN106860907B true CN106860907B (en) | 2019-10-29 |
Family
ID=59164674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611264061.4A Active CN106860907B (en) | 2016-12-30 | 2016-12-30 | A kind of hemostatic gauze |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860907B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5492618A (en) * | 1977-12-30 | 1979-07-23 | Japan Synthetic Rubber Co Ltd | Poultice |
| GB2320502B (en) * | 1996-12-20 | 2000-09-20 | Johnson & Johnson Medical | Bioresorbable alginate derivatives |
| BR0102637A (en) * | 2001-05-17 | 2003-02-25 | Johnson & Johnson Ind Com | Adhesive bandage |
| WO2008019129A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
| CN103394078A (en) * | 2013-07-31 | 2013-11-20 | 中国人民解放军第四军医大学 | Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid |
-
2016
- 2016-12-30 CN CN201611264061.4A patent/CN106860907B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106860907A (en) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI237573B (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| DE69333286T2 (en) | A THROMBIN BLOOD FRACTION FOR USE IN A MEDICAL PROCEDURE | |
| US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
| Vachhrajani et al. | Science of wound healing and dressing materials | |
| CN101121041A (en) | Denaturated starch absorbable hemostatic material and preparation method thereof | |
| CN101485897A (en) | Biocompatible, hemostatic, anti-adhesion, healing-promoting and surgically-occlusive modified starch material | |
| CN101497670A (en) | Biocompatibility pre-gelatinized modified starch and preparation thereof | |
| You et al. | The effective control of a bleeding injury using a medical adhesive containing batroxobin | |
| CN104906626A (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| JP7378486B2 (en) | Medical adhesives, their preparation methods, and their uses | |
| US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
| AT411326B (en) | HEMOSTATIC COLLAGEN PELLETS | |
| CN105816905A (en) | Absorbable bone wax with heal-promoting function and preparation method of absorbable bone wax | |
| Du et al. | Gelatin sponges with a uniform interoperable pore structure and biodegradability for liver injury hemostasis and tissue regeneration | |
| CN105126152B (en) | A kind of gelatin chitosan compound hemostatic powder | |
| CN106860907B (en) | A kind of hemostatic gauze | |
| CN105056280A (en) | Hemostatic material | |
| TR201804823T1 (en) | HEMOSTATIC COMPOSITION | |
| CN108261560A (en) | A kind of degradable absorption hemostatic material of grain containing modified starch nano and its application | |
| CA2896866A1 (en) | Lyophilized fibrin sealant for high volume hemorrhage | |
| WO2021176457A1 (en) | Anti-hemorrhaging compositions | |
| Chen et al. | Facile synthesis of rapid hemostatic powder based on sodium alginate for promoting hemostasis and wound healing | |
| CN106620660A (en) | Bleeding-stopping spray | |
| KR20250101567A (en) | Absorbable hemostatic composition in the body prepared through the fusion of gelatin and kaolin and its manufacturing method | |
| Koyama et al. | Novel Biodegradable Devices Forming Bioadhesive Hydrogels for Hemostatics and Adhesion Barriers (2): Preparation of Hemostatic Sponges and Clinical Application in Dental Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |